Skip to main content

Published locations for Alemtuzumab safety and efficacy persist at 4 years in relapsing-remitting multiple sclerosis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Alemtuzumab safety and efficacy persist at 4 years in relapsing-remitting multiple sclerosis

User login

  • Reset your password
  • /content/alemtuzumab-safety-and-efficacy-persist-4-years-relapsing-remitting-multiple-sclerosis
  • /internalmedicinenews/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4
  • /psychiatry/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4-years
  • /internalmedicine/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4-years
  • /neurology/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4-years-relapsing
  • /clinicalneurologynews/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4
  • /clinicalpsychiatrynews/article/87283/multiple-sclerosis/alemtuzumab-safety-and-efficacy-persist-4